VADs can support the left ventricle (LVAD), the right ventricle (RVAD), or both (BiVAD). However, the LVAD is the only device that patients can leave the hospital with. The HeartMate 3 is the newest type of LVAD that the FDA has approved. It is a small centrifugal pump that uses a fully magnetically rotor to reduce blood cell breakdown.

2024年10月14日 · 植入长期左心室辅助装置（lvad）后的右心室衰竭是死亡率的主要驱动因素。据报道，双心室（bivad）或全人工心脏（tah）植入后的生存率仍明显低于单独使用lvad。近期一项研究报道了heartmate 3（hm 3）单独lvad和bivad植入的临床结果。

Methods: From May 2017 to April 2020, a total of 12 patients underwent implantation of HeartMate 3 (HM3) biventricular VADs (BiVADs) as a bridge to cardiac transplantation. The right-sided pump was implanted in the right atrium in all cases. Adverse events and patient outcomes were determined.

2018年8月17日 · Significant right ventricular failure accompanying left ventricular failure was treated by implantation of the fully magnetically levitated centrifugal HeartMate 3 ventricular assist device as biventricular (BiVAD) support in 14 patients at 6 medical centers worldwide. The clinical details of this first multicenter experience are presented.

The use of a HeartMate 3 as a right ventricular assist device (RVAD) requires several complex technical modifica-tions. Here, we provide step-wise detailed figures and a comprehensive description of bilat-eral HeartMate 3 insertion, with a particular focus on right atrial inflow cannulation for the RVAD.

The introduction of HeartMate 3 (HM3) fully magnetically levitated LVAD generated interest in using it also as a biventricular assist device (BiVAD). The aim of this report is to summarize the current global experience with HM3 as BiVAD.

2023年1月6日 · The use of a HeartMate 3 as a right ventricular assist device (RVAD) requires several complex technical modifications. Here, we provide step-wise detailed figures and a comprehensive description of bilateral HeartMate 3 insertion, with a particular focus on right atrial inflow cannulation for the RVAD.

Objectives: Right ventricular failure following implantation of a durable left ventricular assist device (LVAD) is a major driver of mortality. Reported survival following biventricular (BiVAD) or total artificial heart (TAH) implantation remains substantially inferior to LVAD alone. We report our outcomes with LVAD and BiVAD HeartMate 3 (HM3).

2019年7月15日 · 近年来临床上开始探索对全心衰竭的患者进行标签外的双心室辅助装置（bivad）治疗。 该项研究对来自德国、奥地利、以色列、澳大利亚等国家6个中心在探索最新一代全磁悬浮式左心室辅助装置HeartMate 3进行双心室辅助治疗的经验。

2020年12月28日 · From May 2017 to April 2020, a total of 12 patients underwent implantation of HeartMate 3 (HM3) biventricular VADs (BiVADs) as a bridge to cardiac transplantation. The right-sided pump was implanted in the right atrium in all cases. Adverse events and patient outcomes were determined.